Vienna (OTS) –The world’s fastest growing neurological disease poses major challenges for patients and their families: Parkinson’s disease. In Austria, 20,000 to 30,000 people are currently affected. Good symptom control using oral therapies is possible, especially at the beginning of the disease. This can become more difficult as the disease progresses. Device-assisted therapies can then enable a largely independent life with a good quality of life for many years.
Parkinson’s disease is a progressive neurodegenerative disease. Around 10 million people worldwide are affected by Parkinson’s disease, in Austria between 20,000 and 30,000. The average age of onset is 60-70 years. As life expectancy increases, the frequency of Parkinson’s disease also increases (1).
Although a cure is not yet possible, various symptomatic treatment options are available. Good symptom control using oral therapies is possible, especially at the beginning of the disease. This can become more difficult as the disease progresses.
Device-assisted therapies can then enable a largely independent life with a good quality of life for many years. A new subcutaneous infusion therapy has recently become available here. This offers a continuous infusion under the skin (24 hours/day) of foslevodopa, a prodrug of the active ingredient levodopa, which has been available and well-researched for decades, and foscarbidopa. Other device-assisted therapies include subcutaneous apomorphine infusion therapy, gastrointestinal levodopa pumps and deep brain stimulation.
Education & information
In the MeinMed event series “Parkinson’s disease – current information on diagnosis and therapy” Those affected and their relatives receive information from well-known Parkinson’s experts throughout Austria. After the lecture there will be an opportunity to ask questions. Admission is free, registration is not required.
Here are the dates:
April 10th, 7 p.m. in Innsbruck Priv.-Doz. Dr. Florian Krismer, PhD Women’s Head Clinic, Lecture Hall 1, Anichstrasse 35, 6020 Innsbruck (this is a building on the grounds of the LKH Innsbruck)
April 17th, 7 p.m. in Linz Dr. Thomas Mitterling, PhD Johannes Kepler University – MED CAMPUS I, teaching building (LEH), room LEH 108, Hospitalstraße 5, 4020 Linz
April 23rd, 7 p.m. in Knittelfeld Assoc.Prof. Priv.-Doz. Dr. Petra Schwingenschuh Kulturhaus Knittelfeld, Gaaler Straße 4, 8720 Knittelfeld
April 25th, 7 p.m. in Perchtoldsdorf Dr. Julia Neuhauser Kulturzentrum Perchtoldsdorf, Beatrixgasse 5a, 2380 Perchtoldsdorf
Further information: www.meinparkinson.at
Literature:
1) accessed on January 4, 2024.
About AbbVie
AbbVie’s mission is to develop and deliver innovative medicines and solutions that solve today’s serious health problems and address tomorrow’s medical challenges. The AbbVie team is committed to making a remarkable impact on people’s lives across a range of key therapeutic areas — immunology, oncology, neuroscience and eye care — as well as products and services across the Allergan Aesthetics portfolio. For more information about AbbVie, please visit www.abbvie.at. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
